Recently, Zhongke Borui (Beijing) Technology Co., Ltd. declared the successful completion of its Series B financing round, raising tens of millions of yuan, with Sanze Venture Capital as the key investor. These funds are earmarked for further advancing the company's comprehensive industry chain strategy in the brain-computer interface (BCI) sector. Established in 2017 and nurtured within the Institute of Automation at the Chinese Academy of Sciences, Zhongke Borui operates under the leadership of Chief Scientist Jiang Tianzai, with Zhang Xin holding the positions of Chairman and General Manager. The team's home base, the Brain Network Group Research Center, boasts a wealth of expertise in brain science, offering robust backing for the company's research and development endeavors. Specializing in cerebrovascular diseases, Zhongke Borui is at the forefront of translating photoelectric synchronous brain activity imaging technology into practical applications. The company has developed a cutting-edge multimodal brain function imaging system. Leveraging BCI technology, Zhongke Borui aids in assessing the rehabilitation progress of patients, enhancing treatment efficacy. To date, the company has successfully applied for and obtained over 50 intellectual property rights and introduced a range of groundbreaking medical devices to the market. With a solid technological foundation built on the integration of 'brain-computer interface + artificial intelligence,' Zhongke Borui has established a full-chain industry layout and defined product development paths for three clinical departments. The company is dedicated to creating innovative products and enhancing surgical outcomes. Its pioneering photoelectric synchronous brain function imaging system stands as a testament to the remarkable progress of BCI technology in clinical applications worldwide. Prior to this, Zhongke Borui had already completed a cumulative total of five rounds of financing, laying a strong financial groundwork for its continued growth and innovation.